Printer Friendly

p38 mitogen-activated protein kinase and hematologic malignancies.

The mitogen-activated protein kinase (MAPK) superfamily are proline-directed protein kinases that mediate the effects of numerous extracellular stimuli on a wide array of biologic processes, such as cellular proliferation, differentiation, and death. (1) Three groups of mammalian MAPK have been well documented: the extracellular signal-regulated kinases, the p38 MAPKs, and the c-Jun N[H.sub.2]-terminal kinases. (2) The extracellular signal-regulated kinases are robustly activated by growth factors and phorbol ester but are only weakly activated by cytokines and environmental stress. In contrast, p38 MAPK and c-Jun N[H.sub.2]-terminal kinase are strongly activated by cytokines and environmental stress but are poorly activated by growth factors and phorbol ester.

The p38 MAPK pathway was originally described as a mammalian homolog to a yeast osmolarity sensing pathway. (3) The most well-known role of the p38 pathway is as a transducer of responses to environment stress (such as hyperosmolarity, ultraviolet irradiation, and heat shock) and as receptors binding by proinflammatory molecules (eg, endotoxin, tumor necrosis factor a [TNF-[alpha]], and interleukin [IL] 1). Downstream substrates of p38 MAPK involve a variety of proteins, including kinases, cell cycle and apoptosis regulators, and transcription factors. Additionally, p38 MAPKs also perform posttranscriptional regulation of cytokines such as TNF-[alpha] and IL-1p. (4-8) Thus, p38 MAPK signaling has been implicated in responses ranging from apoptosis to cell cycle, induction of expression of cytokine genes, and differentiation. (9-15) This plethora of activators conveys the complexity of the p38 pathway. This complexity is further complicated by the observation that the specific downstream effects of p38 MAPK activation depends not only on stimuli but also on cell types and perhaps also on various p38 MAPK isoforms involved. (16-18) This review focuses on the recent advancement of p38 MAPK isoforms as well as the role of p38 MAPK in hematologic malignancies.


To activate p38 MAPK by various stimuli, there is a requirement for dual phosphorylation on threonine and tyrosine residues present in specific motifs (threonine-glycine-tyrosine) located in the activation loop. (3,19,20) This phosphorylation is regulated by upstream dual-specificity kinases (MAPK kinases, [MAPKKs]) including MKK3, MKK4, and MKK6, which are capable of phosphorylating MAPKs on both serine and threonine as well as on tyrosine residues. MAPKKs exhibit relative specificity for the substrate MAPK proteins that they phosphorylate. The activation of MAPKKs is regulated by other upstream serine-threonine kinases, called MAPKK kinases, which phosphorylate the MAPKKs on specific serine residues. MAPKK kinases that regulate activation of p38 MAPK include kinases (Mlk1, Mlk2, Mlk3, Dlk, and Lzk), Mekk kinases (Mekk1, Mekk2, Mekk3, and Mekk4), Tak1, Ask1, Ask2, and Tpl- (2.20-26) Activation of the MAPKK kinases or MAPKKs occurs downstream from small G proteins whose function is regulated by the guanine exchange factor proteins. The small G proteins that regulate activation of p38 MAPK include members of the Rho family of proteins (Rac1, Cdc42, RhoA, and RhoB). (11,17,27) Thus, initial activation of guanine exchange factors leads to activation of GTPases and downstream initiation of distinct kinase cascades that regulate the activation of p38 MAPK.



To date, 4 isoforms of the p38 family have been identified: p38[alpha], p38[beta], p38[gamma] (extracellular signal-regulated kinases 6, SAPK3), and p38[delta] (SAPK4). These isoforms are encoded by the genes located at 6p21.3-p21.2 ([alpha]), 22q13.33 ([beta] and [gamma]), and 6p21.31 ([delta]), respectively (28-30) (http://; accessed December 28, 2008). All p38 isoforms are characterized by a threonine-glycine-tyrosine dual-phosphorylation motif. (20,31) Sequence comparisons have revealed that each p38 isoform shares ~60% identity within the p38 group but only 40% to 45% to the other 3 MAPK family members. Of these, p38[alpha] and p38p are ubiquitously expressed in most tissues, whereas p38[gamma] and p38[delta] are differentially expressed depending on tissue type. (19,20) The p38[gamma] gene is highly expressed in muscle and the p38[delta] gene is upregulated in the lung, pancreas, testes, small intestine, kidney, and endocrine glands.

Expression of these isoforms in hematopoietic cells is not well documented. However, differentiation of stage-specific expression of p38 MAPK isoforms has been shown in primary human erythroid cells. In the differentiation of erythroid progenitors, p38[alpha] and p38[gamma] isoforms are continuously expressed throughout differentiation from lineage uncommitted [CD34.sup.+] early hematopoietic cells to terminally differentiated enucleating erythroblasts, which suggests distinct functions for these 2 isoforms in hematopoiesis. (25) On the other hand, p38[beta] is not expressed in differentiating erythroid progenitors. This is in contrast to nonhematopoietic tissues where p38[beta] appears almost universally expressed. Of interest, p38[delta] is expressed during the terminal phase of erythroid differentiation coinciding with the time when erythroid progenitors become erythropoietin independent and cease proliferation. (25) Additionally, p38 MAPK (p38[alpha]) is constitutively activated in low-grade myelodysplastic syndromes (MDSs) and its activation correlates with enhanced apoptosis in MDS bone marrows. (32-34) Using Western blot analysis with antibodies against each p38 isoform for humans, we recently demonstrated that all 4 isoforms ([alpha], [beta], [gamma], [delta]) of p38 MAPK were expressed by human RPMI8226 myeloma cell line (Figure 1, A). By reverse transcription-polymerase chain reaction, the plasma cells directly isolated from multiple myeloma (MM) patient samples (n = 6) using CD138 magnetic beads with AutoMACS (Miltenyi Biotech, Auburn, California) showed expression of messenger RNAs of all 4 isoforms of p38 MAPK (results from a representative case are shown in Figure 1, B). These findings suggest that differential expression of p38 isoforms may contribute to the progression of myeloma.


Previous research has shown that the activation of particular p38 isoforms can be specifically controlled through different upstream regulators and coactivated by various combinations of these regulators. (35) MKK6 phosphorylates and strongly activates p38[alpha], p38[beta], and p38[gamma], whereas MKK3 activates p38[alpha] and p38[gamma] but not p38[beta]. MKK4 activates p38[alpha], weakly activates p38[gamma], and does not activate p38[beta] (Figure 2).

The phosphorylations of p38 isoforms are further differentially regulated depending on phosphatase levels. Under physiologic conditions, MAPK activation is often transient. Many dual-specificity phosphatases have been identified that act upon various members of the MAPK pathway and are grouped as the MAPK phosphatase family. Several members can efficiently dephosphorylate p38[alpha] and p38[beta] (36-38); however, p38[gamma] and p38[delta] are resistant to all known MAPK phosphatase family members. Additionally, other types of phosphatases such as serine/threonine protein phosphatase type 2C have been shown to have a role in downregulating the MAPK pathway. (39)



Despite the substantial structural homology among the isoforms in each group, there is evidence that distinct isoforms exhibit different properties rather than just functional redundancy, although the detailed functions of each isoform remain largely unknown. (16,25) Furthermore, in some cases different isoforms may mediate opposing biologic responses to meet cellular requirements for various intricate and delicate biologic processing of stimulating signals. For example, in breast cancer cell lines, the p38[beta] isoform increases the activation of AP-1 transcriptional activities, whereas p38[gamma] and p38[delta] inhibit AP-1 transcriptional activities. Thus, AP-1-dependent cellular proliferation is simultaneously regulated by p38[beta], p38[gamma], and/or p38[delta] isoforms. These results suggest that an upstream signal of the p38 pathway is interpreted by the expression pattern p38 isoforms, leading to a specific cellular outcome dependent on the spectrum of p38 isoform expression. (40) For example, p38 activation would be stimulatory to the AP-1-dependent transcription if p38[beta] were the major form, whereas it would be inhibitory in cells predominantly expressing p38[gamma] and/or p38[delta].

Thus, the net response in cells expressing all p38 family members is determined by integrations of the positive and the negative regulatory signaling of various isoforms. Furthermore, the enhancing AP-1-dependent transcription effect of p38[beta] is kinase-dependent, because this effect is not seen with the transfection of phosphorylation-dead form p38[beta]/AF. But the inhibition by p38[gamma] and p38[delta] occurs regardless, whether the mutant or the wild-type forms of p38[beta] or p38[delta] is transfected. (40) The latter suggests that the inhibitory function may act through nonkinase functions of p38[gamma] and p38[beta] isoforms. Other studies have also suggested that p38[beta] may be mitogenic and/or antiapoptotic. In HeLa cells, for example, adenovirus-mediated p38[beta] delivery was demonstrated to protect SB202190-induced apoptosis. (41) Furthermore, p38[beta] but not p38[alpha] was shown to protect mesangial cells from TNF-[alpha]-induced apoptosis. (42) Recently, the activation of p38[alpha], but not other isoforms, was required for ras-induced invasion in NIH3T3 cells. (43)

In addition to the findings that each p38 family member has a distinct function, the biologic effects of each isoform may further depend on the individual cellular context. For example, inhibition of p38[gamma] suppressed [gamma]-radiation-induced [G.sub.2] arrest, whereas inhibition of other family members by the dominant negatives had no effect in human osteosarcoma U2OS cells. (44) In contrast, in PC12 cells (a pheochromocytoma cell line), inhibition of p38[alpha] and p38[gamma] counteracted hypoxia-induced [G.sub.0]/[G.sub.1] arrest by increasing cyclin D1 expression. (45) Another example is that green tea polyphenol selectively stimulated p38[delta] phosphorylation leading to the inhibition of AP-1 activity, which resulted in inhibiting cellular proliferation in human breast cancer cell lines. (40) In contrast, this stimulation activated AP-1, which led to cell proliferation in human keratinocytes as a result of simultaneous stimulation of the Ras/MEKK pathways. (46) Together, the p38 MAPK isoforms may lead to cell type-specific and stimulus-specific cellular responses by integrations of the positive and the negative regulatory signaling of various isoforms (Figure 3).



In fission yeast, StyI/Spc1, a homolog of p38 was required for recovery from a stress-induced cell cycle arrest. In mammalian cells, studies have suggested that p38 MAPK activity leads to inhibition of G1 progression via the repression of the cyclin D1 promoter, stabilization and transcriptional induction of p21 protein, and/or the regulation of p53 and RB expression. (12,47-50) Recent reports have also indicated that phosphorylation of p38 MAPK is required for the induction of cell cycle arrest in the G2 phase by ultraviolet light (51) and radiation. (44) This may be associated with the activation of p53, downregulation of cyclin A and B1 expression, or the persistent inhibitory phosphorylation of Cdc2 on Tyr15. (13-15) Nevertheless, the role of p38 isoforms in cell cycles remains largely unknown. Limited studies suggest that exogenous [alpha] and [beta], but not [gamma], isoforms of p38 delay progression into mitosis (52) and that the [alpha] and [gamma] isoforms of p38 have a role in [G.sub.2]-M transitions. (44,53)

p38 MAPK has previously been shown to mediate both proapoptotic (21,54) and antiapoptotic (55,56) signals in different systems, apparently depending on the stimulus and cell type involved. Although the precise mechanisms that account for the generation of such differential responses are unknown, one possibility is that they depend on the variable use of distinct isoforms. In mouse cardiomyocytes, transfection of p38[beta] enhanced cell survival (ie, antiapoptosis), whereas p38[alpha] increase cell death. (56) For its proapoptotic activity, phosphorylation of Bcl-2 family members by activated p38 MAPK has been shown to be a key event in the early induction of apoptosis under cellular stress. bcl-2 phosphorylation by p38[alpha] has been shown to be associated with a decrease in the antiapoptotic potential of bcl-2 protein, leading to caspase activation. Phosphorylation of Bax by activated p38 MAPK could initiate its mitochondria translocation prior to apoptosis. (57-60) Recently, a new p38 MAPK-regulated protein named p18 (Hamlet) was identified. p18 (Hamlet) accumulation requires the activation of p38 MAPK and p18 (Hamlet) phosphorylation by p38 MAPK is essential for its activity. It is demonstrated that p18 (Hamlet) interacts with p53 and stimulates the transcription of several proapoptotic p53 target genes such as PUMA and NOXA. (61) For antiapoptotic activity, increased expression of Bax, cIAP-1/2, XIAP, Smac/Diablo, and survivin has been suggested to be associated with p38 MAPK activation in some cell line models. (62-68) Furthermore, we have recently demonstrated that p38 MAPK activation induces phosphorylation of Hsp27 in MM cells leading to resistance to chemotherapeutic agents in myeloma. (69)


p38 MAPK plays a central role in maintaining the homeostasis of hematopoiesis by balancing, promoting, and inhibiting signals (Figure 4). It is well established that many cytokines and growth factors, including stem cell factor, IL-3, erythropoietin, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and thrombopoietin, regulate normal hematopoietic cell proliferation, survival, and differentiation by activating p38 MAPK pathways to generate their effects. (32,70-74) On the other hand, p38 MAPKs may also play critical roles in the production of hematopoietic growth factors. For example, studies have shown that disruption of p38[alpha] leads to decreasing erythropoietin gene expression in mice. (75) Therefore, p38 MAPK may be critical for developmental erythropoiesis via regulation of erythropoietin expression.

In addition to the activation by hematopoietic growth factors, p38 MAPK can be activated by cytokines that negatively regulate normal hematopoiesis, which include type I interferons (IFNs) (IFN-[alpha], IFN-[beta]). (71,73,76) It has been shown that these cytokines are potent inhibitors of the growth of hematopoietic progenitors of all 3 lineages, including erythroid, myeloid, and megakaryocytic lineage. Moreover, the p38 MAPK pathway, functioning in cooperation with the signal transducer and activation of transcription pathway, is required for regulation of type I IFN-dependent gene transcription. (77) Studies have shown that IFN-[alpha] and IFN-[beta] induce activation of a and p isoforms of p38 MAPK and its downstream effector MAPK activated protein kinase 2 in primary human erythroid progenitors. Furthermore, treatment of normal bone marrow cells with the p38 pharmacologic inhibitors SB203580 and SB202190 reverses the suppressive effects of type I IFNs on normal human hematopoiesis and restores the normal hematopoiesis in MDS hematopoietic cells. In addition to type I IFNs, p38[alpha] and p38[beta] are also activated in primitive human hematopoietic progenitors in response to transforming growth factor [beta] (TGF-[beta]), TNF-[alpha], and type II IFN (IFN-[gamma]) (78-80) treatment. We have recently shown that in the MDS population the -308A/A genotype of the TNF[alpha] gene and the TGF[beta]1 allele + 29T and genotype + 29T/T, each associated with higher levels of expression of TNF[alpha] and TGF[beta]1,were overrepresented, likely through the action of p38 MAPK contribute to the pathology of MDSs. (81) Notably, pharmacologic inhibitors of p38 MAPK reversed the inhibitory effects of these myelosuppressive cytokines on normal human hematopoiesis in vitro. In agreement with the in vitro observation, we have recently shown that the bone marrow samples obtained from patients with MDS markedly increased p38 MAPK activation by immunohistochemis try. (82)


Together these results indicate that p38 MAPK may act as a common signaling mediator for growth inhibitory signals generated by various myelosuppressive cytokines in addition to its role in promoting hematopoiesis via the growth factor. Imbalance of this bidirectional function of p38 MAPK toward the inhibitory side may play an important role in the pathogenesis of certain bone marrow failure syndromes (idiopathic aplastic anemia, paroxysmal nocturnal hemoglobinuria, or subsets of MDS), in which suppression of normal hematopoiesis results from overproduction of myelosuppressive cytokines. In the future, it will be of great interest to further dissect the function of each isoform in hematopoiesis.


The roles of p38 MAPK in acute leukemia (myeloid and lymphocytic) have not been well established. There have been no studies demonstrating a role for constitutive activation of the p38 MAPK pathway in the pathophysiology of acute leukemias. However, p38 MAPK appears to play a role in drug sensitivity in leukemias. It has been shown that inhibition of p38 MAPK using the pharmacologic inhibitors (SB203580 or SB202190) enhances all-trans-retinoic acid--dependent induction of acute promyelocytic leukemia cell differentiation and all-trans-retinoic acid-dependent growth inhibition. (83) These findings indicate that the p38 MAPK pathway plays a negative role in the induction of all-trans-retinoic acid responses in acute promyelocytic leukemia and raises the possibility that combined use of all-trans-retinoic acid with pharmacologic inhibitors of p38 may prove more effective than ATRA alone. Similarly, treatment of NB-4 acute promyelocytic leukemia cells with arsenic trioxide also resulted in the activation of the p38/MAPK activated protein kinase 2 pathway, whereas pharmacologic inhibition of p38 further enhanced arsenic trioxide-induced apoptosis and growth inhibition of acute promyelocytic leukemia cells. (27,84) Additionally, the synergistic/additive effects of combining p38 MAPK inhibition and arsenic trioxide treatment have been seen in chronic myeloid leukemia (CML) (27) as well as myeloma cells recently shown by us. (69)

The p38 MAPK pathway has been shown to play roles in the pathogenesis and pathophysiology of CML. The RhoGEF domain of BCR can activate p38 and the function of p38 is required for BCR-regulated activation of nuclear factor-[kappa]B. Other studies have shown that the function of the p38 pathway is essential for the suppression of growth of CML cells by IFN-[alpha]. The IFN-[alpha] treatment of peripheral blood granulocytes from CML patients induces phosphorylation/activation of p38 in vitro and addition of pharmacologic inhibitors of p38 in CML bone marrow cultures reverses the suppressive effects of IFN-[alpha]. These results indicate that the activation of the p38 signaling cascade may be essential for the antileukemic effects of IFN-[alpha] in CML cells. (85-87)

The p38 pathway seems to play an important role in the effects of rituximab in chronic lymphocytic leukemia. p38 and its downstream effector, MAPK activated protein kinase 2, were activated during the culture of chronic lymphocytic leukemia cells with anti-CD20, whereas the treatment with the p38 pharmacologic inhibitor SB203580 resulted in the induction of apoptosis of the malignant lymphocytes. (88)


Studies have suggested that the TNF-[alpha]--inducible proliferation of non-Hodgkin lymphoma cell lines depends on the activation of p38 MAPK. (89,90) Furthermore, it has also been demonstrated that p38 MAPK regulated TNF-[alpha] production. Therefore, p38 may both regulate TNF-[alpha] expression and mediate signals regulating growth of lymphoma cells upon its activation by TNF-[alpha]. (89,91)

The p38 MAPK pathways may also play roles in growth factors that promote cell proliferation of the malignant cells in Hodgkin lymphoma. Aberrant expression of c-Jun and JunB, downstream of p38 MAPK pathways, has been suggested to participate in the proliferation of Hodgkin lymphoma cells using cell line models. Constitutively activated AP-1 and overexpression of c-Jun and JunB were found in primary tumor cells from Hodgkin lymphoma patients. Finally, studies have shown that p38 is activated in Hodgkin lymphoma cell lines by the receptor activated nuclear factor-[kappa]B ligand, a factor regulating cytokine/chemokine secretion in Reed-Sternberg cells via autocrine mechanisms. (92,93)


There is evidence that the p38 pathway indirectly promotes the growth of MM cells in response to growth factors of myeloma cells (such as IL-6, IL-10, insulin-like growth factor 1, and granulocytic colony-stimulating factor). A recent study demonstrated that a specific p38 MAPK inhibitor (VX-745) can inhibit IL-6 and vascular endothelial growth factor secretion in bone marrow stromal cells and that p38 MAPK inhibition blocks proliferation of MM cells upon contacting marrow stromal cells. (94,95) This is likely because p38 MAPK inhibition leads to inhibiting IL-6 secretion induced by adherence of malignant plasmacytes to bone marrow stromal cells, a major molecule for the survival and proliferation of myeloma cells. These results suggest that the p38 MAPK pathway is essential for paracrine secretion of IL-6 in MM bone marrows and also raises the possibility that targeting the p38 MAPK pathway and its specific isoforms may have therapeutic implications in the treatment of MM.


p38 MAPK plays an important role in cell fate decision. It is shown to mediate a wide array of biologic responses, including regulation of cell cycle, apoptosis, and differentiation. In some hematologic systems, activation of p38 plays a key role of promoting or inhibiting hematopoietic growth with the former leading to hematologic malignancies and the latter resulting in marrow failure. Additionally, p38 activation may increase resistance to chemotherapeutic agents. The importance of different p38 isoforms in various cellular functions has been recently acknowledged. Further understanding of these isoforms will allow designing more specific inhibitors to target particular isoforms to maximize the treatment effect and minimize the side effects for treating hematopoietic malignancies.

We would like to express our deepest appreciation to Brandi Smith-Irving, MS, for her help of critically reading this manuscript. The work is support in part by a The Methodist Hospital Research Institute, Houston, Texas, and the Weill Medical College of Cornell University, New York, New York, collaborative grant to C.C.


(1.) Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1 996;74(10): 589-607.

(2.) Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci. 1994; 19(11):470-473.

(3.) Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994;265(5173):808-811.

(4.) McLaughlin MM, Kumar S, McDonnell PC, et al. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem. 1996;271(14):8488-8492.

(5.) Huang CK, Zhan L, Ai Y, Jongstra J. LSP1 is the major substrate for mitogen-activated protein kinase-activated protein kinase 2 in human neutrophils. J Biol Chem. 1997;272(1):17-19.

(6.) Thomas G, Haavik J, Cohen P. Participation of a stress-activated protein kinase cascade in the activation of tyrosine hydroxylase in chromaffin cells. Eur J Biochem. 1997;247(3):1180-1189.

(7.) Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. Mitogen activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol. 2001;21(19):6461-6469.

(8.) Pierrat B, Correia JS, Mary JL, Tomas-Zuber M, Lesslauer W. RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38alpha mitogen-activated protein kinase (p38alphaMAPK). J Biol Chem. 1998; 273(45):29661-29671.

(9.) Lewis JS, Vijayanathan V, Thomas TJ, et al. Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res. 2005;15(3):113-128.

(10.) Marderosian M, Sharma A, Funk AP, et al. Tristetraprolin regulates cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene. 2006;25(47):6277-6290.

(11.) Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem. 2005;280(12):10964-10973.

(12.) Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002;277(33):29792-29802.

(13.) Chen Y, Miao ZH, Zhao WM, Ding J. The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11'-dideoxyverticillin-induced G2/M arrest. FEBS Lett. 2005;579(17):3683-3690.

(14.) Pedraza-Alva G, Koulnis M, Charland C, et al. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces aG2/M cell cycle checkpoint. EMBO J. 2006;25(4):763-773.

(15.) Yih LH, Hsueh SW, Luu WS, Chiu TH, LeeTC. Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells. Carcinogenesis. 2005;26(1):53-63.

(16.) Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle. 2006;5(8):824-828.

(17.) Bulavin DV, Fornace AJ Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95-118.

(18.) Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004;4(4):372-377.

(19.) Jiang Y, Gram H, Zhao M, et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem. 1997;272(48):30122-30128.

(20.) Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem. 1997; 272(38):23668-23674.

(21.) Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275(5296):90-94.

(22.) Enslen H, Brancho DM, Davis RJ. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. EMBO J. 2000;19(6):1301-1311.

(23.) Schoorlemmer J, Goldfarb M. Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. J Biol Chem. 2002;277(51):49111-49119.

(24.) Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science. 1998;280(5363): 599-602.

(25.) Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA. 2004;101(1):147-152.

(26.) Ohta T, Eguchi R, Suzuki A, Miyakaze S, Ayuzawa R, Kaji K. Hypoxia-induced apoptosis and tube breakdown are regulated by p38 MAPK but not by caspase cascade in an in vitro capillary model composed of human endothelial cells. J Cell Physiol. 2007;211(3):673-681.

(27.) Verma A, Mohindru M, Deb DK, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem. 2002;277(47):44988-44995.

(28.) McDonnell PC, DiLella AG, Lee JC, Young PR. Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6q21.3/21.2. Genomics. 1 995;2 9(1):301-302.

(29.) Goedert M, Hasegawa J, Craxton M, Leversha MA, Clegg S. Assignment of the human stress-activated protein kinase-3 gene (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization. Genomics. 1997;41(3):501-502.

(30.) Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem. 1996;271(30): 17920-17926.

(31.) Hanks SK, Hunter T. Protein kinases 6: the eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995; 9(8):576-596.

(32.) Zhou L, Opalinska J, Verma A. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure. Cell Cycle. 2007;6(5):534-537.

(33.) Navas TA, Mohindru M, Estes M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006;108(13):4170-4177.

(34.) Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12(4):446-451.

(35.) Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273(3):1741-1748.

(36.) Camps M, Nichols A, Gillieron C, et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science. 1998; 280(5367):1262-1265.

(37.) Muda M, Theodosiou A, Rodrigues N, et al. The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen activated protein kinases. J Biol Chem. 1996;271(44):27205-27208.

(38.) Tanoue T, Yamamoto T, Maeda R, Nishida E. A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem. 2001;276(28):26629-26639.

(39.) Meskiene I, Baudouin E, Schweighofer A, et al. Stress-induced protein phosphatase 2C is a negative regulator of a mitogen-activated protein kinase. J Biol Chem. 2003;278(21):18945-18952.

(40.) Pramanik R, Qi X, Borowicz S, et al. p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun: the determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem. 2003; 278(7):4831-4839.

(41.) Nemoto S, Xiang J, Huang S, Lin A. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998;273(26):16415-16420.

(42.) Guo YL, Kang B, Han J, Williamson JR. p38beta MAP kinase protects rat mesangial cells from TNF-alpha-induced apoptosis. J Cell Biochem. 2001;82(4): 556-565.

(43.) Behren A, Binder K, Vucelic G, et al. The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells. Exp Cell Res. 2005;303(2): 321-330.

(44.) Wang X, McGowan CH, Zhao M, et al. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol. 2000;20(13):4543-4552.

(45.) Conrad PW, Rust RT, Han J, Millhorn DE, Beitner-Johnson D. Selective activation of p38alpha and p38gamma by hypoxia: role in regulation of cyclin D1 by hypoxia in PC12 cells. J Biol Chem. 1999;274(33):23570-23576.

(46.) Balasubramanian S, Efimova T, Eckert RL. Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. J Biol Chem. 2002;277(3):1828-1836.

(47.) Molnar A, Theodoras AM, Zon LI, Kyriakis JM. Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK. J Biol Chem. 1997;272(20):13229-13235.

(48.) Bulavin DV, Amundson SA, Fornace AJ. p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev. 2002; 12(1):92-97.

(49.) Wang SW, Pawlowski J, Wathen ST, Kinney SD, Lichenstein HS, Manthey CL. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm Res. 1999;48(10):533-538.

(50.) Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res. 2003;27(11):999-1007.

(51.) Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001;411(6833):102-107.

(52.) Mikhailov A, Shinohara M, Rieder CL. The p38-mediated stress-activated checkpoint: a rapid response system for delaying progression through antephase and entry into mitosis. Cell Cycle. 2005;4(1):57-62.

(53.) Yee AS, Paulson EK, McDevitt MA, et al. The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. Gene. 2004;336(1):1-13.

(54.) Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270(5240):1326-1331.

(55.) Pugazhenthi S, Miller E, Sable C, et al. Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem. 1999;274(39):27529-27535.

(56.) Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273(4):2161-2168.

(57.) De Chiara G, Marcocci ME, Torcia M, et al. Bcl-2 Phosphorylation byp38 MAPK: identification of target sites and biologic consequences. J Biol Chem. 2006;281(30):21353-21361.

(58.) Choi SY, Kim MJ, Kang CM, et al. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J Biol Chem. 2006;281(11):7049-7059.

(59.) Capano M, Crompton M. Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J. 2006;395(1):57-64.

(60.) Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem. 2006;281(30):21256-21265.

(61.) Cuadrado A, Lafarga V, Cheung PC, et al. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J. 2007;26(8):2115-2126.

(62.) Furusu A, Nakayama K, Xu Q, Konta T, Kitamura M. MAP kinase-dependent, NF-kappaB-independent regulation of inhibitor of apoptosis protein genes by TNF-alpha. J Cell Physiol. 2007;210(3):703-710.

(63.) Sethi G, Ahn KS, Xia D, Kurie JM, Aggarwal BB. Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene products. J Immunol. 2007;179(3):1926-1933.

(64.) Seo SK, Lee HC, Woo SH, et al. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis. 2007;12(1):195 209.

(65.) Cheng Y, Chang LW, Tsou TC. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol. 2006;80(6):310-318.

(66.) RudolfE, RudolfK, Cervinka M. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol. 2007.

(67.) Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 2003;22(13):2034-2044.

(68.) Stoica BA, Movsesyan VA, Knoblach SM, Faden AI. Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins. Mol Cell Neurosci. 2005;29(3):355-371.

(69.) Wen J, Cheng HY, Feng Y, et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol. 2008;140(2): 169-180.

(70.) Nagata Y, Moriguchi T, Nishida E, Todokoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood. 1997;90(3):929-934.

(71.) Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002; 277(10):7726-7735.

(72.) Kim JM, White JM, Shaw AS, Sleckman BP. MAPK p38 alpha is dispensable for lymphocyte development and proliferation. J Immunol. 2005;174(3):1239-1244.

(73.) Katsoulidis E, Li Y, Mears H, Platanias LC. The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res. 2005;25(12):749-756.

(74.) Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood. 2000;96(3):933-940.

(75.) Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell. 2000;102(2):221-231.

(76.) Katsoulidis E, Li Y, Yoon P, et al. Role of the p38 mitogen-activated protein-kinase pathway in cytokine-mediated hematopoietic suppression in myelodys-plastic syndromes. Cancer Res. 2005;65(19):9029-9037.

(77.) Uddin S, Lekmine F, Sharma N, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent-transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem. 2000; 275(36):27634-27640.

(78.) Rincon M, Enslen H, Raingeaud J, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 1998;17(10):2817-2829.

(79.) Lee J, Shin JS, Park JY, et al. p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis-inducing ligand induced by interferon-gamma in fetal brain astrocytes. J Neurosci Res. 2003;74(6): 884-890.

(80.) Otero M, Lago R, Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci. 2007;81(19-20):1452-1460.

(81.) Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 2007;131(12):1789-1793.

(82.) Shahjahan M, Dunphy CH, Ewton A, et al. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. Am J Clin Pathol. 2008;130(4):635-641.

(83.) Alsayed Y, Uddin S, Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem. 2001;276(6):4012-4019.

(84.) Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia. 2002;16(4):683-692.

(85.) Korus M, Mahon GM, Cheng L, Whitehead IP. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene. 2002;21(30): 4601-4612.

(86.) Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem. 2001;276(30):28570-28577.

(87.) Chen CH, Lin JY, Liu FH, Chang JL, Huang HM. Basic fibroblast growth factor inhibits p38-mediated cell differentiation and growth inhibition by activin A but not by histone deacetylase inhibitors in CML cells. Ann Hematol. 2008; 87(3):175-182.

(88.) Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent-mechanism. Blood. 2002;99(4):1314-1319.

(89.) Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999;1(2):94-97.

(90.) Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667-4679.

(91.) Dong C, Davis RJ, Flavell RA. MAP kinases in the immuneresponse. Annu Rev Immunol. 2002;20:55-72.

(92.) Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21(15):4104-4113.

(93.) Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98(9):2784-2790.

(94.) Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101(2): 703-705.

(95.) Nguyen AN, Stebbins EG, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res. 2006;312(10): 1909-1923.

Yongdong Feng, MD, PhD; Jianguo Wen, PhD; Chung-Che (Jeff) Chang, MD, PhD

Accepted for publication January 13, 2009.

From the Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, Texas (Drs Feng, Wen, and Chang); the Department of Surgery, Tongji Hospital, Tongji Medical College in Huangzhong University of Science and Technology, Wuhan, P. R. China (Dr Feng); and the Department of Pathology, Weill Medical College of Cornell University, New York, New York (Dr Chang).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Chung-Che (Jeff) Chang, MD, PhD, Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin, MS205, Houston, TX 77030 (e-mail: jeffchang@
COPYRIGHT 2009 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Feng, Yongdong; Wen, Jianguo; Chang, Chung-Che
Publication:Archives of Pathology & Laboratory Medicine
Article Type:Report
Date:Nov 1, 2009
Previous Article:Standards to support information systems integration in anatomic pathology.
Next Article:Sarcomatoid chromophobe renal cell carcinoma with heterologous sarcomatoid elements: a case report and review of the literature.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |